{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:56:53Z","timestamp":1776254213249,"version":"3.50.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00198-025-07726-4","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:59:43Z","timestamp":1763636383000},"page":"605-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of skeletal-related events and fracture prevention in systemic mastocytosis"],"prefix":"10.1007","volume":"37","author":[{"given":"Emily M.","family":"Lunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Lacount","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loren Wissner","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-1971","authenticated-orcid":false,"given":"Kamyar","family":"Asadipooya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"9","key":"7726_CR1","first-page":"2048","volume":"9","author":"C Ustun","year":"2025","unstructured":"Ustun C, Keklik Karadag F, Linden MA, Valent P, Akin C (2025) Systemic mastocytosis: current status and challenges in 2024. Blood Adv 9(9):2048\u20132062","journal-title":"Blood Adv"},{"key":"7726_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06475-y","author":"A Syal","year":"2025","unstructured":"Syal A, Toh J, McInerney A, Tremblay D (2025) The evaluation, management, and future of indolent systemic mastocytosis. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-025-06475-y","journal-title":"Ann Hematol"},{"key":"7726_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","volume":"18","author":"P Valent","year":"2023","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD, Galli SJ (2023) New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol 18:361\u2013386","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"7726_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ajh.26962","volume":"98","author":"A Pardanani","year":"2023","unstructured":"Pardanani A (2023) Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol 98(7):1097\u20131116","journal-title":"Am J Hematol"},{"key":"7726_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011270","author":"CW Jackson","year":"2021","unstructured":"Jackson CW, Pratt CM, Rupprecht CP, Pattanaik D, Krishnaswamy G (2021) Mastocytosis and mast cell activation disorders: clearing the air. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222011270","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7726_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","volume":"482","author":"RJ Leguit","year":"2023","unstructured":"Leguit RJ, Wang SA, George TI, Tzankov A, Orazi A (2023) The international consensus classification of mastocytosis and related entities. Virchows Arch 482(1):99\u2013112","journal-title":"Virchows Arch"},{"issue":"5","key":"7726_CR7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","volume":"131","author":"JJ van Doormaal","year":"2013","unstructured":"van Doormaal JJ, Arends S, Brunekreeft KL, van der Wal VB, Sietsma J, van Voorst Vader PC, Oude Elberink JN, Kluin-Nelemans JC, van der Veer E, de Monchy JG (2013) Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol 131(5):1429\u20131431.e1421","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"7726_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vestergaard H, Kristensen T, M\u00f8ller M, Bindslev-Jensen C, Fryzek JP, Broesby-Olsen S (2014) Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166(4):521\u2013528","journal-title":"Br J Haematol"},{"issue":"2","key":"7726_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","volume":"34","author":"K Brockow","year":"2014","unstructured":"Brockow K (2014) Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am 34(2):283\u2013295","journal-title":"Immunol Allergy Clin North Am"},{"key":"7726_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246380","author":"R Zanotti","year":"2021","unstructured":"Zanotti R, Bonifacio M, Isolan C, Tanasi I, Crosera L, Olivieri F, Orsolini G, Schena D, Bonadonna P (2021) A multidisciplinary diagnostic approach reveals a higher prevalence of indolent systemic mastocytosis: 15-years\u2019 experience of the GISM network. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13246380","journal-title":"Cancers (Basel)"},{"key":"7726_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163942","author":"J Ungerstedt","year":"2022","unstructured":"Ungerstedt J, Ljung C, Klimkowska M, G\u00fclen T (2022) Clinical outcomes of adults with systemic mastocytosis: a 15-year multidisciplinary experience. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14163942","journal-title":"Cancers (Basel)"},{"key":"7726_CR12","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1182\/blood-2023-188451","volume":"142","author":"MPP Joergensen","year":"2023","unstructured":"Joergensen MPP, Oevlisen AK, Jakobsen LH, El-Galaly TCC, Severinsen MT (2023) Incidence and prevalence of mastocytosis in adults: a Danish Nationwide Register Study. Blood 142:6339","journal-title":"Blood"},{"key":"7726_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/1651-226X.2024.31406","volume":"63","author":"A Bergstr\u00f6m","year":"2024","unstructured":"Bergstr\u00f6m A, H\u00e4gglund H, Berglund A, Nilsson G, Lambe M (2024) Epidemiology of mastocytosis: a population-based study (Sweden). Acta Oncol 63:44\u201350","journal-title":"Acta Oncol"},{"issue":"11","key":"7726_CR14","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/all.15396","volume":"77","author":"K Franke","year":"2022","unstructured":"Franke K, Kirchner M, Mertins P, Zuberbier T, Babina M (2022) The SCF\/KIT axis in human mast cells: Capicua acts as potent KIT repressor and ERK predominates PI3K. Allergy 77(11):3337\u20133349","journal-title":"Allergy"},{"issue":"6","key":"7726_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jaci.2022.04.012","volume":"149","author":"M Tsai","year":"2022","unstructured":"Tsai M, Valent P, Galli SJ (2022) KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol 149(6):1845\u20131854","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"7726_CR16","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.jaip.2022.05.034","volume":"10","author":"J Gotlib","year":"2022","unstructured":"Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, Carter MC, Hartmann K, \u00c1lvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Hoermann G, Sperr WR, Elberink HO, Siebenhaar F, Butterfield JH, Ustun C, Zanotti R, Triggiani M, Schwartz LB, Lyons JJ, Orfao A, Sotlar K, Horny HP, Arock M, Metcalfe DD, Akin C, L\u00fcbke J, Valent P, Reiter A (2022) Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis. J Allergy Clin Immunol Pract 10(8):2025\u20132038.e2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"7726_CR17","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.jaip.2022.05.037","volume":"10","author":"P Pyatilova","year":"2022","unstructured":"Pyatilova P, Akin C, Alvarez-Twose I, Arock M, Bonadonna P, Brockow K, Butterfield JH, Broesby-Olsen S, Carter MC, Castells M, George TI, Gotlib J, Greiner G, G\u00fclen T, Hartmann K, Hermine O, Horny HP, Jawhar M, Lange M, Lyons JJ, Maurer M, Metcalfe DD, Nedoszytko B, Niedoszytko M, Orfao A, Reiter A, Schwaab J, Sotlar K, Sperr WR, Triggiani M, Valent P, Siebenhaar F (2022) Refined treatment response criteria for indolent systemic mastocytosis proposed by the ECNM-AIM consortium. J Allergy Clin Immunol Pract 10(8):2015\u20132024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"7726_CR18","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/all.14248","volume":"75","author":"J Trizuljak","year":"2020","unstructured":"Trizuljak J, Sperr WR, Nekvindov\u00e1 L, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, Bonifacio M, Perkins C, Elena C, Malcovati L, Fortina AB, Shoumariyeh K, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, von Bubnoff N, Yavuz AS, H\u00e4gglund H, Mattsson M, Panse J, J\u00e4kel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brockow K, Bretterklieber A, Niedoszytko M, van Anrooij B, Reiter A, Gotlib J, Kluin-Nelemans HC, Mayer J, Doubek M, Valent P (2020) Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy 75(8):1927\u20131938","journal-title":"Allergy"},{"issue":"3","key":"7726_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30400-2","volume":"8","author":"JI Mu\u00f1oz-Gonz\u00e1lez","year":"2021","unstructured":"Mu\u00f1oz-Gonz\u00e1lez JI, \u00c1lvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, Sperr WR, Shoumariyeh K, Schwaab J, Greiner G, Henriques A, Caldas C, Fern\u00e1ndez-Gim\u00e9nez C, S\u00e1nchez-Mu\u00f1oz L, Mayado A, P\u00e9rez-Pons A, Schmitt-Graeff A, Duyster J, Tanasi I, Olivieri F, Mora-Caster\u00e1 E, Luna I, Senent L, Ba\u00f1as MH, Nu\u00f1ez-Garc\u00eda A, Jurado-Chac\u00f3n M, Mart\u00edn-S\u00e1nchez G, Colado E, Xicoy B, Gener-Ric\u00f3s G, Gotlib J, Bonadonna P, Reiter A, Valent P, Garc\u00eda-Montero AC, Orfao A (2021) Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematol 8(3):e194\u2013e204","journal-title":"Lancet Haematol"},{"issue":"5","key":"7726_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood.2018886507","volume":"134","author":"JI Mu\u00f1oz-Gonz\u00e1lez","year":"2019","unstructured":"Mu\u00f1oz-Gonz\u00e1lez JI, \u00c1lvarez-Twose I, Jara-Acevedo M, Henriques A, Vi\u00f1as E, Prieto C, S\u00e1nchez-Mu\u00f1oz L, Caldas C, Mayado A, Matito A, Dasilva-Freire N, Orfao A, Garc\u00eda-Montero AC (2019) Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood 134(5):456\u2013468","journal-title":"Blood"},{"issue":"16","key":"7726_CR21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2019000932","volume":"135","author":"A Reiter","year":"2020","unstructured":"Reiter A, George TI, Gotlib J (2020) New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood 135(16):1365\u20131376","journal-title":"Blood"},{"issue":"6","key":"7726_CR22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.jaci.2022.04.004","volume":"149","author":"M Arock","year":"2022","unstructured":"Arock M, Hoermann G, Sotlar K, Hermine O, Sperr WR, Hartmann K, Brockow K, Akin C, Triggiani M, Broesby-Olsen S, Reiter A, Gotlib J, Horny HP, Orfao A, Metcalfe DD, Valent P (2022) Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: status 2022. J Allergy Clin Immunol 149(6):1855\u20131865","journal-title":"J Allergy Clin Immunol"},{"key":"7726_CR23","doi-asserted-by":"crossref","unstructured":"McLornan DP, Czerw T, Damaj G, Ethell M, Gurnari C, Hern\u00e1ndez-Boluda JC, Polverelli N, Schwaab J, Sockel K, Raffaella G, Onida F, S\u00e1nchez-Ortega I, Battipaglia G, Elena C, Gotlib J, Reiter A, Rossignol J, Ustun C, Valent P, Yakoub-Agha I, Radia DH. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee. Leukemia. 2024.","DOI":"10.1038\/s41375-024-02182-1"},{"issue":"11","key":"7726_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, Elberink HO, Butterfield JH, George TI, Greiner G, Ustun C, Bonadonna P, Sotlar K, Nilsson G, Jawhar M, Siebenhaar F, Broesby-Olsen S, Yavuz S, Zanotti R, Lange M, Nedoszytko B, Hoermann G, Castells M, Radia DH, Mu\u00f1oz-Gonzalez JI, Sperr WR, Triggiani M, Kluin-Nelemans HC, Galli SJ, Schwartz LB, Reiter A, Orfao A, Gotlib J, Arock M, Horny HP, Metcalfe DD (2021) Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere 5(11):e646","journal-title":"Hemasphere"},{"issue":"9","key":"7726_CR25","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3109\/10428194.2012.763121","volume":"54","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Sever M, Cortes J, Kantarjian H, Verstovsek S (2013) Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma 54(9):1959\u20131964","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"7726_CR26","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood.V116.21.3073.3073","volume":"116","author":"A Quint\u00c1s-Cardama","year":"2010","unstructured":"Quint\u00c1s-Cardama A, Sever M, Cortes JE, Kantarjian HM, Verstovsek S (2010) Change in mast cell bone marrow burden and in serum tryptase level are not accurate markers of response in patients with systemic mastocytosis. Blood 116(21):3073","journal-title":"Blood"},{"issue":"2","key":"7726_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F (2022) Secondary osteoporosis. Endocr Rev 43(2):240\u2013313","journal-title":"Endocr Rev"},{"issue":"8","key":"7726_CR28","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","volume":"27","author":"M Rossini","year":"2016","unstructured":"Rossini M, Zanotti R, Orsolini G, Tripi G, Viapiana O, Idolazzi L, Zam\u00f2 A, Bonadonna P, Kunnathully V, Adami S, Gatti D (2016) Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 27(8):2411\u20132421","journal-title":"Osteoporos Int"},{"issue":"3","key":"7726_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","volume":"17","author":"LW Greene","year":"2016","unstructured":"Greene LW, Asadipooya K, Corradi PF, Akin C (2016) Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord 17(3):419\u2013431","journal-title":"Rev Endocr Metab Disord"},{"key":"7726_CR30","doi-asserted-by":"crossref","unstructured":"Asadipooya K, Greene LW (2020) Systemic mastocytosis and bone-related events. In: Akin C (ed) Mastocytosis: A Comprehensive Guide. Springer International Publishing, Cham, pp 123\u2013140","DOI":"10.1007\/978-3-030-27820-5_8"},{"issue":"6","key":"7726_CR31","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00198-019-04918-7","volume":"30","author":"Y Degbo\u00e9","year":"2019","unstructured":"Degbo\u00e9 Y, Eischen M, Apoil PA, Mailhol C, Dubreuil P, Hermine O, Paul C, Bulai Livideanu C, Laroche M (2019) Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. Osteoporos Int 30(6):1235\u20131241","journal-title":"Osteoporos Int"},{"issue":"3","key":"7726_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.iac.2018.04.013","volume":"38","author":"G Orsolini","year":"2018","unstructured":"Orsolini G, Viapiana O, Rossini M, Bonifacio M, Zanotti R (2018) Bone disease in mastocytosis. Immunol Allergy Clin North Am 38(3):443\u2013454","journal-title":"Immunol Allergy Clin North Am"},{"key":"7726_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bone.2017.09.005","volume":"105","author":"Y Degbo\u00e9","year":"2017","unstructured":"Degbo\u00e9 Y, Eischen M, Nigon D, Apoil PA, Mailhol C, Tournier E, Laurent C, Hanssens K, Hermine O, Paul C, Laroche M, Bulai-Livideanu C (2017) Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone 105:219\u2013225","journal-title":"Bone"},{"issue":"11","key":"7726_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/ajh.24490","volume":"91","author":"S Broesby-Olsen","year":"2016","unstructured":"Broesby-Olsen S, Farkas DK, Vestergaard H, Hermann AP, M\u00f8ller MB, Mortz CG, Kristensen TK, Bindslev-Jensen C, S\u00f8rensen HT, Frederiksen H (2016) Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol 91(11):1069\u20131075","journal-title":"Am J Hematol"},{"issue":"6","key":"7726_CR35","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","volume":"134","author":"E van der Veer","year":"2014","unstructured":"van der Veer E, Arends S, van der Hoek S, Versluijs JB, de Monchy JGR, Oude Elberink JNG, van Doormaal JJ (2014) Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol 134(6):1413\u20131421","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"7726_CR36","first-page":"1306","volume":"12","author":"Y Degbo\u00e9","year":"2024","unstructured":"Degbo\u00e9 Y, Severino-Freire M, Couture G, Apoil PA, Gaudenzio N, Hermine O, Ruyssen-Witrand A, Paul C, Laroche M, Constantin A, Livideanu CB (2024) The prevalence of osteoporosis is low in adult cutaneous mastocytosis patients. The Journal of Allergy and Clinical Immunology: In Practice 12(5):1306\u20131312","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"4","key":"7726_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-019-03119-3","volume":"146","author":"P Riffel","year":"2020","unstructured":"Riffel P, Schwaab J, Lutz C, Naumann N, Metzgeroth G, Fabarius A, Schoenberg SO, Hofmann WK, Valent P, Reiter A, Jawhar M (2020) An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. J Cancer Res Clin Oncol 146(4):945\u2013951","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"7726_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.55563\/clinexprheumatol\/y4ksv9","volume":"39","author":"HJ Meyer","year":"2021","unstructured":"Meyer HJ, P\u00f6nisch W, Monecke A, Gundermann P, Surov A (2021) Bone mineral density in patients with systemic mastocytosis: correlations with clinical and histopathological features. Clin Exp Rheumatol 39(1):52\u201357","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"7726_CR39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00223-021-00887-4","volume":"109","author":"M Gehlen","year":"2021","unstructured":"Gehlen M, Schmidt N, Pfeifer M, Balasingam S, Schwarz-Eywill M, Maier A, Werner M, Siggelkow H (2021) Osteoporosis caused by systemic mastocytosis: prevalence in a cohort of 8392 patients with osteoporosis. Calcif Tissue Int 109(6):685\u2013695","journal-title":"Calcif Tissue Int"},{"key":"7726_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117141","volume":"186","author":"I Tanasi","year":"2024","unstructured":"Tanasi I, Crosera L, Taus F, Orsolini G, Adami G, Olivieri F, Bernardelli A, Bonadonna P, Nalin F, Sella S, Giannini S, Liu Y, Mannelli F, Vanderwert F, Bonifacio M, Krampera M, Rossini M, Lyons JJ, Zanotti R (2024) Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal. Bone 186:117141","journal-title":"Bone"},{"issue":"1","key":"7726_CR41","doi-asserted-by":"publisher","first-page":"75.e71","DOI":"10.1016\/j.amjmed.2012.07.018","volume":"126","author":"N Guillaume","year":"2013","unstructured":"Guillaume N, Desoutter J, Chandesris O, Merlusca L, Henry I, Georgin-Lavialle S, Barete S, Hirsch I, Bouredji D, Royer B, Gruson B, Lok C, Sevestre H, Mentaverri R, Brazier M, Meynier J, Hermine O, Marolleau JP, Kamel S, Damaj G (2013) Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 126(1):75.e71\u201377","journal-title":"Am J Med"},{"issue":"12","key":"7726_CR42","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1016\/j.jaip.2021.08.001","volume":"9","author":"A Makovoz","year":"2021","unstructured":"Makovoz A, Wang J, Oshegbo G, Park YH, Lyons JJ, Eisch AR, Scott LM, Reynolds JC, Ortega-Villa AM, Metcalfe DD, Komarow HD (2021) Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort. J Allergy Clin Immunol Pract 9(12):4459\u20134467.e4410","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"7726_CR43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","volume":"124","author":"L Escribano","year":"2009","unstructured":"Escribano L, Alvarez-Twose I, S\u00e1nchez-Mu\u00f1oz L, Garcia-Montero A, N\u00fa\u00f1ez R, Almeida J, Jara-Acevedo M, Teod\u00f3sio C, Garc\u00eda-Cos\u00edo M, Bellas C, Orfao A (2009) Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124(3):514\u2013521","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"7726_CR44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-020-05804-3","volume":"32","author":"WF Lems","year":"2021","unstructured":"Lems WF, Paccou J, Zhang J, Fuggle NR, Chandran M, Harvey NC, Cooper C, Javaid K, Ferrari S, Akesson KE (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int 32(3):399\u2013411","journal-title":"Osteoporos Int"},{"issue":"6","key":"7726_CR45","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00223-020-00749-5","volume":"107","author":"FM Ulivieri","year":"2020","unstructured":"Ulivieri FM, Rinaudo L, Piodi LP, Barbieri V, Marotta G, Scium\u00e8 M, Grifoni FI, Cesana BM (2020) Usefulness of dual X-ray absorptiometry-derived bone geometry and structural indexes in mastocytosis. Calcif Tissue Int 107(6):551\u2013558","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"7726_CR46","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","volume":"49","author":"M Rossini","year":"2011","unstructured":"Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49(4):880\u2013885","journal-title":"Bone"},{"issue":"8","key":"7726_CR47","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","volume":"24","author":"S Seitz","year":"2013","unstructured":"Seitz S, Barvencik F, Koehne T, Priemel M, Pogoda P, Semler J, Minne H, Pfeiffer M, Zustin J, P\u00fcschel K, Eulenburg C, Schinke T, Amling M (2013) Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 24(8):2325\u20132334","journal-title":"Osteoporos Int"},{"issue":"10","key":"7726_CR48","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/ard.2009.124511","volume":"69","author":"S Barete","year":"2010","unstructured":"Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billemont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Franc\u00e8s C (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69(10):1838\u20131841","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7726_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00223-015-9969-5","volume":"96","author":"M Rossini","year":"2015","unstructured":"Rossini M, Viapiana O, Zanotti R, Tripi G, Perbellini O, Idolazzi L, Bonifacio M, Adami S, Gatti D (2015) Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcif Tissue Int 96(5):410\u2013416","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"7726_CR50","first-page":"1536","volume":"11","author":"TA Rama","year":"2023","unstructured":"Rama TA, Henriques AF, Matito A, Jara-Acevedo M, Caldas C, Mayado A, Mu\u00f1oz-Gonz\u00e1lez JI, Moreira A, Cavaleiro-Rufo J, Garc\u00eda-Montero A, \u00d3rf\u00e3o A, Sanchez-Mu\u00f1oz L, \u00c1lvarez-Twose I (2023) Bone and cytokine markers associated with bone disease in systemic mastocytosis. The Journal of Allergy and Clinical Immunology: In Practice 11(5):1536\u20131547","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"3","key":"7726_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s00223-023-01107-x","volume":"113","author":"AS Franco","year":"2023","unstructured":"Franco AS, Murai IH, Takayama L, Caparbo VF, Marchi LL, Velloso E, Pereira RMR (2023) Assessment of bone microarchitecture in patients with systemic mastocytosis and its association with clinical and biochemical parameters of the disease. Calcif Tissue Int 113(3):276\u2013285","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"7726_CR52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","volume":"34","author":"M Rossini","year":"2014","unstructured":"Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L, Bonadonna P, Schena D, Escribano L, Adami S, Gatti D (2014) Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am 34(2):383\u2013396","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"7726_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ageing\/25.1.1","volume":"25","author":"C Johansson","year":"1996","unstructured":"Johansson C, Roupe G, Lindstedt G, Mellstr\u00f6m D (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25(1):1\u20137","journal-title":"Age Ageing"},{"issue":"10","key":"7726_CR54","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1016\/j.jaip.2020.06.054","volume":"8","author":"MC Onnes","year":"2020","unstructured":"Onnes MC, van Doormaal JJ, van der Veer E, Versluijs JB, Arends S, Oude Elberink HNG (2020) Fracture risk reduction by bisphosphonates in mastocytosis? J Allergy Clin Immunol Pract 8(10):3557\u20133564","journal-title":"J Allergy Clin Immunol Pract"},{"key":"7726_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117578","volume":"200","author":"C Wilke","year":"2025","unstructured":"Wilke C, Blaschke M, Lamersdorf A, Heppner C, Metz M, Horny HP, Werner M, Lippert U, Siggelkow H (2025) The number of vertebral fractures in indolent systemic mastocytosis is influenced by presence of the KIT-mutation. Bone 200:117578","journal-title":"Bone"},{"issue":"1","key":"7726_CR56","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12885-022-10498-3","volume":"23","author":"TO Tiryaki","year":"2023","unstructured":"Tiryaki TO, \u00d6zkan SG, Erdem S, Aday AD, Hindilerden \u0130Y, Gelincik A, Baykal C, Yegen G, Do\u011fan \u0130, B\u00fcy\u00fckbabani N, Nal\u00e7ac\u0131 M, Yavuz AS (2023) Comprehensive mastocytosis data analysis from a single center. BMC Cancer 23(1):82","journal-title":"BMC Cancer"},{"key":"7726_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5785378","volume":"2020","author":"G Carosi","year":"2020","unstructured":"Carosi G, Guabello G, Longhi M, Grifoni F, Passeri E, Corbetta S (2020) Hypertryptasemia and mast cell-related disorders in severe osteoporotic patients. Mediators Inflamm 2020:5785378","journal-title":"Mediators Inflamm"},{"issue":"345","key":"7726_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.morpho.2020.01.004","volume":"104","author":"B Bouvard","year":"2020","unstructured":"Bouvard B, Pascaretti-Grizon F, Legrand E, Lavigne C, Audran M, Chappard D (2020) Bone lesions in systemic mastocytosis: bone histomorphometry and histopathological mechanisms. Morphologie 104(345):97\u2013108","journal-title":"Morphologie"},{"issue":"6","key":"7726_CR59","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","volume":"100","author":"G Orsolini","year":"2017","unstructured":"Orsolini G, Gavioli I, Tripi G, Viapiana O, Gatti D, Idolazzi L, Zanotti R, Rossini M (2017) Denosumab for the treatment of mastocytosis-related osteoporosis: a case series. Calcif Tissue Int 100(6):595\u2013598","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"7726_CR60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00223-016-0198-3","volume":"100","author":"A Artuso","year":"2017","unstructured":"Artuso A, Caimmi C, Tripi G, Viapiana O, Bonifacio M, Idolazzi L, Gavioli I, Gatti D, Zanotti R, Rossini M (2017) Longitudinal evaluation of bone mineral density and bone metabolism markers in patients with indolent systemic mastocytosis without osteoporosis. Calcif Tissue Int 100(1):40\u201346","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"7726_CR61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4274\/tjh.2013.0170","volume":"32","author":"N Alpay Kan\u0131tez","year":"2015","unstructured":"Alpay Kan\u0131tez N, Erer B, Do\u011fan \u00d6, B\u00fcy\u00fckbabani N, Baykal C, Sindel D, Tanakol R, Yavuz AS (2015) Osteoporosis and osteopathy markers in patients with mastocytosis. Turk J Haematol 32(1):43\u201350","journal-title":"Turk J Haematol"},{"issue":"3","key":"7726_CR62","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","volume":"67","author":"E van der Veer","year":"2012","unstructured":"van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67(3):431\u2013438","journal-title":"Allergy"},{"issue":"8","key":"7726_CR63","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","volume":"124","author":"M Laroche","year":"2011","unstructured":"Laroche M, Livideanu C, Paul C, Cantagrel A (2011) Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 124(8):776\u2013778","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"7726_CR64","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/S0049-3848(14)50017-5","volume":"133","author":"D Ribatti","year":"2014","unstructured":"Ribatti D, Moschetta M, Vacca A (2014) Microenvironment and multiple myeloma spread. Thromb Res 133(Suppl 2):S102\u2013106","journal-title":"Thromb Res"},{"key":"7726_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2023.101669","volume":"18","author":"HA Tirado","year":"2023","unstructured":"Tirado HA, Balasundaram N, Laaouimir L, Erdem A, van Gastel N (2023) Metabolic crosstalk between stromal and malignant cells in the bone marrow niche. Bone Rep 18:101669","journal-title":"Bone Rep"},{"key":"7726_CR66","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","volume":"40","author":"T Ono","year":"2020","unstructured":"Ono T, Hayashi M, Sasaki F, Nakashima T (2020) RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen 40:2","journal-title":"Inflamm Regen"},{"key":"7726_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6910312","volume":"2020","author":"M Tobeiha","year":"2020","unstructured":"Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S (2020) RANKL\/RANK\/OPG pathway: a mechanism involved in exercise-induced bone remodeling. BioMed Res Int 2020:6910312","journal-title":"BioMed Res Int"},{"issue":"7","key":"7726_CR68","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/ATVBAHA.119.312371","volume":"39","author":"K Asadipooya","year":"2019","unstructured":"Asadipooya K, Weinstock A (2019) Cardiovascular outcomes of romosozumab and protective role of alendronate. Arterioscler Thromb Vasc Biol 39(7):1343\u20131350","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7726_CR69","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.lfs.2018.08.019","volume":"209","author":"Y Huang","year":"2018","unstructured":"Huang Y, Liu L, Liu A (2018) Dickkopf-1: current knowledge and related diseases. Life Sci 209:249\u2013254","journal-title":"Life Sci"},{"issue":"1","key":"7726_CR70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41598-024-83851-0","volume":"15","author":"A Szudy-Szczyrek","year":"2025","unstructured":"Szudy-Szczyrek A, Mlak R, Pigo\u0144-Zaj\u0105c D, Krupski W, Mazurek M, Tomczak A, Chromik K, G\u00f3rska A, Ko\u017alik P, Juda A, Koko\u0107 A, Dubaj M, Sacha T, Niedoszytko M, Helbig G, Szczyrek M, Szumi\u0142o J, Ma\u0142ecka-Massalska T, Hus M (2025) Role of sclerostin in mastocytosis bone disease. Sci Rep 15(1):161","journal-title":"Sci Rep"},{"issue":"5","key":"7726_CR71","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","volume":"132","author":"A Rabenhorst","year":"2013","unstructured":"Rabenhorst A, Christopeit B, Leja S, Gerbaulet A, Kleiner S, F\u00f6rster A, Raap U, Wickenhauser C, Hartmann K (2013) Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 132(5):1234\u20131237.e1237","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"7726_CR72","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jaci.2013.02.019","volume":"132","author":"S Broesby-Olsen","year":"2013","unstructured":"Broesby-Olsen S, Kristensen T, Vestergaard H, Brixen K, M\u00f8ller MB, Bindslev-Jensen C (2013) Kit D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol 132(3):723\u2013728","journal-title":"J Allergy Clin Immunol"},{"key":"7726_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102487","author":"O Gonz\u00e1lez-L\u00f3pez","year":"2022","unstructured":"Gonz\u00e1lez-L\u00f3pez O, Mu\u00f1oz-Gonz\u00e1lez JI, Orfao A, \u00c1lvarez-Twose I, Garc\u00eda-Montero AC (2022) Comprehensive analysis of acquired genetic variants and their prognostic impact in systemic mastocytosis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14102487","journal-title":"Cancers (Basel)"},{"issue":"2","key":"7726_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/ejh.12043","volume":"90","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S (2013) Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 90(2):89\u201398","journal-title":"Eur J Haematol"},{"issue":"1","key":"7726_CR75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/187152806775269303","volume":"5","author":"L Escribano","year":"2006","unstructured":"Escribano L, Akin C, Castells M, Schwartz LB (2006) Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy-Drug Targets 5(1):61\u201377","journal-title":"Inflamm Allergy-Drug Targets"},{"issue":"2","key":"7726_CR76","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","volume":"26","author":"M Laroche","year":"2007","unstructured":"Laroche M, Bret J, Brouchet A, Mazi\u00e8res B (2007) Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 26(2):242\u2013243","journal-title":"Clin Rheumatol"},{"issue":"11","key":"7726_CR77","doi-asserted-by":"publisher","first-page":"1127.e1121","DOI":"10.1016\/j.amjmed.2014.06.015","volume":"127","author":"M Rossini","year":"2014","unstructured":"Rossini M, Zanotti R, Viapiana O, Tripi G, Idolazzi L, Biondan M, Orsolini G, Bonadonna P, Adami S, Gatti D (2014) Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 127(11):1127.e1121\u20131127.e1124","journal-title":"Am J Med"},{"issue":"1","key":"7726_CR78","first-page":"2","volume":"10","author":"JA Parker","year":"2024","unstructured":"Parker JA, Hou R (2024) A 48-year-old man with a hip fracture and skin rash: a case report. AACE Clin Case Rep 10(1):2\u20136","journal-title":"AACE Clin Case Rep"},{"issue":"10","key":"7726_CR79","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1016\/j.jaip.2023.06.045","volume":"11","author":"IFA Bocca-Tjeertes","year":"2023","unstructured":"Bocca-Tjeertes IFA, Boot AM, Brand HK, van Doormaal JJ, Oude Elberink HNG (2023) Vertebral fracture in a 7-year-old boy with indolent systemic mastocytosis. J Allergy Clin Immunol Pract 11(10):3269\u20133271","journal-title":"J Allergy Clin Immunol Pract"},{"key":"7726_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.156018","volume":"159","author":"JH Lim","year":"2022","unstructured":"Lim JH, Kim HY, Kang HG, Jeong HJ, Kim HM (2022) RANKL down-regulates the mast cell proliferation through inducing senescence. Cytokine 159:156018","journal-title":"Cytokine"},{"issue":"3","key":"7726_CR81","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00198-020-05704-6","volume":"32","author":"D Rosenberg","year":"2021","unstructured":"Rosenberg D, Avni T, Tsvetov G, Gafter-Gvili A, Diker-Cohen T (2021) Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 32(3):413\u2013424","journal-title":"Osteoporos Int"},{"key":"7726_CR82","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz322","author":"T Diker-Cohen","year":"2020","unstructured":"Diker-Cohen T, Rosenberg D, Avni T, Shepshelovich D, Tsvetov G, Gafter-Gvili A (2020) Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz322","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"7726_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-022-06423-w","volume":"33","author":"C Sk\u00f6ld","year":"2022","unstructured":"Sk\u00f6ld C, Kultima K, Freyhult E, Larsson A, Gordh T, Hailer NP, Mallmin H (2022) Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial. Osteoporos Int 33(9):1\u20138","journal-title":"Osteoporos Int"},{"key":"7726_CR84","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-22-0408","author":"M Wang","year":"2023","unstructured":"Wang M, Seibel MJ (2023) Skin and bones: systemic mastocytosis and bone. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-22-0408","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"7726_CR85","doi-asserted-by":"crossref","unstructured":"Baldo BA, Baldo BA (2016) Monoclonal antibodies: introduction. Safety of Biologics Therapy: Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins. 29\u201356.","DOI":"10.1007\/978-3-319-30472-4_2"},{"issue":"6","key":"7726_CR86","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2500\/aap.2016.37.3987","volume":"37","author":"FA Bonilla","year":"2016","unstructured":"Bonilla FA (2016) Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 37(6):426\u2013431","journal-title":"Allergy Asthma Proc"},{"key":"7726_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13223-015-0097-6","volume":"11","author":"D Guti\u00e9rrez-Fern\u00e1ndez","year":"2015","unstructured":"Guti\u00e9rrez-Fern\u00e1ndez D, Cruz MJ, Foncubierta-Fern\u00e1ndez A, Moreno-Ancillo A, Fern\u00e1ndez-Anguita MJ, Medina-Varo F, Andres-Garc\u00eda JA (2015) Monoclonal antibody desensitization in a patient with a generalized urticarial reaction following denosumab administration. Allergy Asthma Clin Immunol 11:29","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"7726_CR88","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0025-7753(07)72541-1","volume":"128","author":"M Sall\u00e9s","year":"2007","unstructured":"Sall\u00e9s M, Holgado S, Navarro JT, Ribera JM, Riera E, Mill\u00e0 F, Tena X (2007) [Osteoporosis as a first manifestation of systemic mastocytosis. Study of 6 cases]. Med Clin (Barc) 128(6):216\u2013218","journal-title":"Med Clin (Barc)"},{"key":"7726_CR89","doi-asserted-by":"publisher","first-page":"1401187","DOI":"10.3389\/falgy.2024.1401187","volume":"5","author":"MJ Hamilton","year":"2024","unstructured":"Hamilton MJ, Greene LW, Madigan LM, Wang SA, Arana Yi C, Kuykendall A, George TI, Castells MC (2024) Case report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms. Front Allergy 5:1401187","journal-title":"Front Allergy"},{"issue":"3","key":"7726_CR90","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/jbmr.1765","volume":"28","author":"RS Dhillon","year":"2013","unstructured":"Dhillon RS, Xie C, Tyler W, Calvi LM, Awad HA, Zuscik MJ, O\u2019Keefe RJ, Schwarz EM (2013) Pth-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis. J Bone Miner Res 28(3):586\u2013597","journal-title":"J Bone Miner Res"},{"issue":"9","key":"7726_CR91","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/jbmr.3178","volume":"32","author":"L Zhang","year":"2017","unstructured":"Zhang L, Wang T, Chang M, Kaiser C, Kim JD, Wu T, Cao X, Zhang X, Schwarz EM (2017) Teriparatide treatment improves bone defect healing via anabolic effects on new bone formation and non-anabolic effects on inhibition of mast cells in a murine cranial window model. J Bone Miner Res 32(9):1870\u20131883","journal-title":"J Bone Miner Res"},{"issue":"9","key":"7726_CR92","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/exd.13288","volume":"26","author":"TC Theoharides","year":"2017","unstructured":"Theoharides TC (2017) Neuroendocrinology of mast cells: challenges and controversies. Exp Dermatol 26(9):751\u2013759","journal-title":"Exp Dermatol"},{"issue":"7","key":"7726_CR93","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/jbmr.49","volume":"25","author":"RT Turner","year":"2010","unstructured":"Turner RT, Iwaniec UT, Marley K, Sibonga JD (2010) The role of mast cells in parathyroid bone disease. J Bone Miner Res 25(7):1637\u20131649","journal-title":"J Bone Miner Res"},{"key":"7726_CR94","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2048987","volume":"2016","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Nishijima M, Tashiro K, Kawabata K (2016) Wnt-\u03b2-catenin signaling promotes the maturation of mast cells. Biomed Res Int 2016:2048987","journal-title":"Biomed Res Int"},{"issue":"1","key":"7726_CR95","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","volume":"8","author":"J Jing","year":"2023","unstructured":"Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y, Zhou C (2023) Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct Target Ther 8(1):315","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"7726_CR96","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1182\/blood.2020010207","volume":"138","author":"L Polivka","year":"2021","unstructured":"Polivka L, Parietti V, Bruneau J, Soucie E, Madrange M, Bayard E, Rignault R, Canioni D, Fraitag S, Lhermitte L, Feroul M, Tissandier M, Rossignol J, Frenzel L, Cagnard N, Meni C, Bouktit H, Collange AF, Gougoula C, Parisot M, Bader-Meunier B, Livideanu C, Laurent C, Arock M, Hadj-Rabia S, R\u00fcther U, Dubreuil P, Bodemer C, Hermine O, Maouche-Chr\u00e9tien L (2021) The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. Blood 138(23):2396\u20132407","journal-title":"Blood"},{"issue":"11","key":"7726_CR97","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/jbmr.5650051104","volume":"5","author":"L Graves 3rd","year":"1990","unstructured":"Graves L 3rd, Stechschulte DJ, Morris DC, Lukert BP (1990) Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. Journal of bone and mineral research\u202f: the official journal of the American Society for Bone and Mineral Research 5(11):1113\u20131119","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"issue":"1","key":"7726_CR98","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF00663015","volume":"72","author":"R Weide","year":"1996","unstructured":"Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfl\u00fcger KH (1996) Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 72(1):41\u201343","journal-title":"Ann Hematol"},{"issue":"2","key":"7726_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.532","volume":"155","author":"F Siebenhaar","year":"2025","unstructured":"Siebenhaar F, Alvarez-Twose I, Sundaresh V, Hartmann K, Maurer M, Broesby-Olsen S, George T, Lin H-M, Lampson B, Akin C (2025) Avapritinib and bone health in indolent systemic mastocytosis: learnings from the PIONEER trial. J Allergy Clin Immunol 155(2):AB168","journal-title":"J Allergy Clin Immunol"},{"key":"7726_CR100","doi-asserted-by":"publisher","first-page":"13","DOI":"10.18632\/oncoscience.614","volume":"12","author":"A Kalfoutzou","year":"2025","unstructured":"Kalfoutzou A, Spanou K, Mylonakis A, Lagopoulou V, Dimitrakoudi M, Korovila A, Piperis C, Tsiouri E, Mostratou E (2025) Breaking point: systemic mastocytosis manifesting as severe osteoporosis. Oncoscience 12:13\u201320","journal-title":"Oncoscience"},{"issue":"5","key":"7726_CR101","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.eprac.2024.03.311","volume":"30","author":"D Maxwell","year":"2024","unstructured":"Maxwell D, Shakir MK, Hoang T (2024) # 1706102 systemic mastocytosis, a rare cause of secondary osteoporosis. Endocr Pract 30(5):S93\u2013S94","journal-title":"Endocr Pract"},{"key":"7726_CR102","doi-asserted-by":"publisher","first-page":"169","DOI":"10.11604\/pamj.2019.32.169.16640","volume":"32","author":"VV Garla","year":"2019","unstructured":"Garla VV, Chaudhary KUQ, Yaqub A (2019) Systemic mastocytosis: a rare cause of osteoporosis. Pan Afr Med J 32:169","journal-title":"Pan Afr Med J"},{"issue":"6","key":"7726_CR103","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1136\/ard.2004.029116","volume":"64","author":"AY Lim","year":"2005","unstructured":"Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64(6):965\u2013966","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7726_CR104","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","volume":"36","author":"A Marshall","year":"1997","unstructured":"Marshall A, Kavanagh RT, Crisp AJ (1997) The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 36(3):393\u2013396","journal-title":"Br J Rheumatol"},{"issue":"3","key":"7726_CR105","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","volume":"8","author":"T Cundy","year":"1987","unstructured":"Cundy T, Beneton MN, Darby AJ, Marshall WJ, Kanis JA (1987) Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 8(3):149\u2013155","journal-title":"Bone"},{"issue":"4","key":"7726_CR106","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/ACI.0000000000001079","volume":"25","author":"G Costanzo","year":"2025","unstructured":"Costanzo G, Marzio V, Cavagli\u00e0 E, Paoletti G, Heffler E (2025) New treatments for systemic mastocytosis in 2025. Curr Opin Allergy Clin Immunol 25(4):277\u2013292","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07726-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:05:12Z","timestamp":1776251112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7726"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07726-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}